←

JNJ · Johnson & Johnson

Healthcare NYQ United States jnj.com ↗
Val — — Gro — — Qua — — Mom — — Sta — — Cap— P/S6.57 P/E— Fwd P/E23.33 PEG3.02 52W— – — RSI— Target$279.41 (+3.1%) Beta0.21 Div1.96%
Loading chart…
RSI ()
◈ Pattern Overlays
Loading patterns…
Drug Manufacturers - General New Brunswick, United States 138,200 employees
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low — 52W High
Position in Range —
RSI (14)
0 · Oversold RSI 59 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
5Bearish
0Neutral

Key Signals 1

▼ Double Top Major reversal 2026-10-01 · $260.68
Two peaks ~$278.15 — bearish reversal confirmed
Learn more →

Momentum Signals 8

▲ MACD Bullish Crossover 2026-07-27 · $265.95
▲ MACD Bullish Crossover 2026-08-18 · $271.11
▲ MACD Bullish Crossover 2026-09-02 · $275.21
▲ MACD Bullish Crossover 2026-10-21 · $257.78

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Jan 26, 2027
Beat Rate 100%
Consensus BUY
Analyst Upside +3.1%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
16
6
1
BuyHoldSell
Price Target Range
$279.41 +3.1% upside
Low $190 — High $320
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 67.77%Last 12 Months
Operating Margin 25.74%Last 12 Months
Return on Equity 20.02%Last 12 Months
Revenue Growth 5.90%Year over Year
Free Cash Flow 18.50BLast 12 Months
Free Cash Flow Yield —Last 12 Months
Balance Sheet
Debt / Equity 54.77Most Recent Quarter
Current Ratio 1.02Most Recent Quarter
Cash 17.23BMost Recent Quarter
Total Debt 44.65BMost Recent Quarter
Net Debt —Most Recent Quarter
How JNJ Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap652.48B
Enterprise Value679.90B
Trailing P/E41.13
Forward P/E23.33
PEG Ratio (5yr)3.02
Price/Sales (ttm)6.57
Price/Book (mrq)8.00
EV/Revenue6.84
EV/EBITDA19.71
Share Statistics
Avg Vol (3m)6.88M
Shares Outstanding2.41B
Float2.40B
% Held by Insiders0.05%
% Held by Institutions76.78%
Short Ratio2.23
Short % of Float0.78%
Profitability
Gross Margin67.77%
Operating Margin (ttm)25.74%
Profit Margin16.20%
Return on Assets (ttm)8.46%
Return on Equity (ttm)20.02%
Income Statement
Revenue (ttm)99.33B
Revenue Growth (yoy)5.90%
Gross Profit (ttm)67.32B
EBITDA34.50B
Net Income (ttm)16.09B
Diluted EPS (ttm)6.59
EPS Growth (yoy)-95.90%
Balance Sheet
Total Cash (mrq)17.23B
Total Debt (mrq)44.65B
Debt / Equity (mrq)54.77
Current Ratio (mrq)1.02
Book Value / Share33.87
Operating CF (ttm)26.16B
Free Cash Flow (ttm)18.50B
Trading & Dividends
Beta (5Y)0.21
50-Day MA265.45
200-Day MA246.40
Fwd Dividend Yield1.99%
Payout Ratio80.12%
Income
Dividend Yield 1.96%Last 12 Months
Annual Rate 5.36Forward
Payout Ratio 80.12%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 80.12%
Monthly Dividends
Ownership Breakdown
Institutional 76.78% Insider 0.05% Public 23.2%
Short Interest 0.78% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in JNJ in their latest SEC 13F filing.

Loading…
Insider Transactions
Open-market buys & sells · one dot per day, sized by $ · follows the filters below
Date Insider Role Transaction Shares Price Value